Section Arrow
Quote
KROS.NASDAQ
- Keros Therapeutics
Quotes are at least 15-min delayed:2025/11/16 15:29 EST
Regular Hours
Last
 17.26
-0.04 (-0.23%)
Day High 
17.63 
Prev. Close
17.3 
1-M High
17.63 
Volume 
989.82K 
Bid
17.01
Ask
17.26
Day Low
17.12 
Open
17.24 
1-M Low
13.6 
Market Cap 
527.06M 
Currency USD 
P/E 11.09 
%Yield -- 
10-SMA 16.27 
20-SMA 15.65 
50-SMA 15.63 
52-W High 72.37 
52-W Low 9.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.56/-2.96
Enterprise Value
543.95M
Balance Sheet
Book Value Per Share
23.09
Cash Flow
Cash Flow Yield
0.13
Income Statement
Total Revenue
3.55M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 15:29 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.